Algernon Pharmaceuticals 

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada, Australia, and New Zealand. The company's pipeline includes Ifenprodil, which completed Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in preclinical stage for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which has completed preclinical stage for the treatment of strokes. The company was formerly known as “Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.